What investment strategy does AdBio Partners focus on?

AdBio Partners focuses on VC strategies in the private equity space.

How many portfolio companies does AdBio Partners have?

AdBio Partners has 20 active portfolio companies and 2 completed exits and 2 funds tracked on GP Intel.

Where is AdBio Partners headquartered?

AdBio Partners is headquartered in Paris, France.

What is AdBio Partners's assets under management?

AdBio Partners manages approximately €133M in assets under management.

When was AdBio Partners founded?

AdBio Partners was founded in 2015.

What sectors does AdBio Partners invest in?

AdBio Partners invests across Healthcare.

Home/GPs/AdBio Partners

AdBio Partners

Paris, France·Founded 2015·

Venture Capital

·adbio.partners

AdBio partners, founded in 2016 and based in Paris, France, is a venture capital firm specializing in early-stage investments in promising life sciences startups across Europe. It focuses on building pioneering healthcare companies by…Read full bio

AUM

€133M

Funds

Portfolio

Exits

SectorsHealthcare

Key facts

HQParis, France

Founded2015

Websiteadbio.partners

Recent exits

Agomab Therapeutics

Healthcare · 2026

Univercells

Biotech · 2024

Coverage notes

2 funds tracked, 22 portfolio companies (20 active · 2 realized). Verified weekly from public filings and deal announcements.

About AdBio Partners

AdBio partners is a French venture capital firm with €133 million of assets under management, founded in 2016 and headquartered in Paris. The firm specialises in early-stage investments in promising life sciences startups across Europe, focusing on building pioneering healthcare companies by partnering closely with scientific founders and management teams.

Investment thesis

AdBio Partners targets European life sciences startups at seed and Series A-B stages, with sector focus on biotech (drug discovery and development), MedTech and selective HealthTech verticals. Equity ticket sizes typically range from €1 million seed positions through to €10 million Series A-B follow-on commitments. The life sciences-exclusive mandate enables deep scientific and clinical expertise across portfolio companies, distinguishing AdBio from generalist VC peers.

Recent activity

Recent realised exits include Agomab Therapeutics (healthcare, 2026) and Univercells (biotech, 2024), reflecting active distribution across the life sciences portfolio. The platform tracks 2 funds, 20 active portfolio companies and 2 realised exits across the multi-vintage European life sciences programme. Detailed buyer names and multiple data available on Pro at €49/month.